Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TAREGET LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES MODEL
4.2 PESTEL ANALYSIS
5 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: REGULATIONS
5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES
5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE
6 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY
7 RESEARCH AND DEVELOPMENT ANALYSIS: NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
7.1 PIPELINE ANALYSIS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS
8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.1.3 INCREASING GOVERNMENT FUNDING
8.1.4 INCREASING PRIVATE SECTOR FUNDING
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY
8.2.2 LACK OF SKILLED PROFESSIONALS
8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY
8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE
8.3 OPPORTUNITIES
8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS
8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.3 INCREASING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY
8.4.2 LACK OF PROPER REGULATORY GUIDELINES
9 IMPACT OF COVID-19 ON NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
9.1 IMPACT ON THE PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY
9.4 STRATEGIC INITIATIVES BY MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET
10.1 OVERVIEW
10.2 STAPHYLOCOCCUS
10.3 ESCHERICHIA COLI
10.4 PSEUDOMONAS
10.5 STREPTOCOCCUS
10.6 SALMONELLA
10.7 OTHERS
11 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE
11.1 OVERVIEW
11.2 LYTIC
11.3 LYSOGENIC
12 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE
12.1 OVERVIEW
12.2 STERILE BROTH CULTURE
12.3 WATER-SOLUBLE JELLY BASE
13 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 POSTOPERATIVE WOUND INFECTIONS
13.3 INFECTIONS OF SKIN AND NASAL MUCOSA
13.4 BACTERIAL DYSENTERY
13.5 SUPPURATIVE SKIN INFECTIONS
13.6 LUNG AND PLEURAL INFECTION
13.7 OTHERS
14 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 LIQUID
14.2.2 TABLET
14.3 DERMAL
14.4 PARENTERAL
14.4.1 INTRAVENOUSLY
14.4.2 INTRAPLEURAL INJECTIONS
14.5 OTHERS
15 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECILAITY CLINICS
15.4 ACADEMIC RESEARCH & INSTITUTES
15.5 OTHERS
16 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTORS
17 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
18 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 MICROGEN
20.1.1 COMPANY SNAPSHOT
20.1.2 COMPANY SHARE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 ADAPTIVE PHAGE THERAPEUTICS
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 PHAGELUX,INC
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 LOCUS BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ATCC
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 INTRALYTIX, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 MICREOS
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 PYLUM
20.8.1 COMPANY SNAPSHOT
20.8.2 TECHNOLOGY PORTFOLIO
20.8.3 RECENT DEVELOPMENTS
20.9 FIXED-PHAGE LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ARMATA PHARMACEUTICALS, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 ARTHUR ANDREW MEDICAL
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 CYTOPHAGE TECHNOLOGIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 ENBIOTIX, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENTS
20.14 INTODEWORLD, INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 NEXTBIOTICS
20.15.1 COMPANY SNAPSHOT
20.15.2 TECHNOLOGY PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 PHERECYDES PHARMA
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 U.S. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 47 U.S. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 U.S. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 49 U.S. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 U.S. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 51 U.S. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 52 U.S. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 U.S. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 U.S. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 CANADA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 56 CANADA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 CANADA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 58 CANADA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 CANADA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 CANADA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 CANADA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 CANADA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE NORTH AMERICA BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA BACTERIOPHAGES THERAPY MARKET
FIGURE 15 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020
FIGURE 16 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE
FIGURE 19 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020
FIGURE 20 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020
FIGURE 24 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020
FIGURE 28 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020
FIGURE 36 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 44 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 48 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 49 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 50 EUROPE BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 51 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
